Clinical AI Governance — The Next Fund Category
1/
Clinical AI is emerging as its own fund category.
Not just healthtech. Not just medtech. Not just AI.
It’s where governance becomes the moat — not invention.
2/
Across healthcare, AI pilots are expanding fast.
But only 30% reach production.
Why? Governance, oversight, and operational readiness are missing.
3/
In clinical AI, validation ≠ deployment.
A model can work. A pilot can validate.
But without governance, capital stays trapped and revenue timing stretches.
4/
The real moat is converting validated pilots into governed, live systems.
That’s where capital either compounds or stalls.
5/
This is why clinical AI deserves its own fund category.
Deployment conditioning inside regulated environments drives capital efficiency.
6/
LPs are asking new questions:
Not “Do we have AI exposure in healthcare?”
But “Do our managers understand how clinical AI actually scales?”
7/
Africa has a leapfrog opportunity.
Less than 5% of projects include governance.
We can define standards tailored to multilingual, resource-constrained realities.
8/
The next generation of specialist managers will win by helping companies cross the boundary from pilot to governed deployment — faster.
9/
This is the conversation we need to start now.
Clinical AI governance is not congested — it’s wide open.
And Africa can lead.
@SciforAfrica
@GPAI_PMIA
@OECDinnovation
@AAAiH_AU
English
